

BIOMAP Network

Christian-Albrechts-Universität zu Kiel

King's College London

Karolinska Institutet

Academisch Ziekenhuis Leiden

Université du Luxembourg

Tampereen Yliopisto/Tampere University

Klinikum rechts der Isar der Technischen
Universität München

AIT Austrian Institute of Technology GmbH

Universitätsklinikum Hamburg-Eppendorf

University of Bristol

University of Dundee

Københavns Universitet

Den Selvejende Institution Dansk
Børneastma Center

Radboud University Medical Center

Tartu Ülikool/University of Tartu

Centre Hospitalier Universitaire Vaudois

Itä-Suomen Yliopisto/University of Eastern
Finland

Heinrich-Heine-Universität Düsseldorf

Trinity College Dublin

Academisch Medisch Centrum Universiteit
van Amsterdam

Information Technology for Translational
Medicine

Hahn-Schickard-Gesellschaft für angewandte
Forschung e.V.

London School of Hygiene & Tropical
Medicine

EURICE – European Research and Project
Office GmbH

Universität Wien

Sanofi-Aventis Deutschland GmbH

LEO Pharma A/S

Boehringer Ingelheim International GmbH

Pfizer Limited

UCB Biopharma SPRL

Technische Universität München

www.biomap-imi.eu

Follow us on twitter
[@Biomap_IMI](https://twitter.com/Biomap_IMI)



Coordination

Christian-Albrechts-Universität zu Kiel

Prof. Stephan Weidinger

sweidinger@dermatology.uni-kiel.de

Project Lead

Sanofi-Aventis Deutschland GmbH

Dr Paul Bryce

paul.bryce@sanofi.com

Project Management

Eurice GmbH

Dr Juliane Kirsch & Dr Bianca Dibari

j.kirsch@eurice.eu

b.dibari@eurice.eu



Biomap

Biomarkers in Atopic Dermatitis and Psoriasis

www.biomap-imi.eu



efpia

BIOMAP has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 821511. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

About BIOMAP

Atopic dermatitis and psoriasis affect more than 300 million people worldwide and are highly variable in terms of onset, severity, progression over time and response to treatment.

Resulting in significant morbidity and an increased risk for associated conditions such as arthritis and asthma, inflammatory skin diseases are a huge burden to patients and families, care-givers and healthcare systems.

BIOMAP will examine the causes and mechanisms of these conditions by identifying the biomarkers responsible for the variation in disease outcome. Taking advantage of recent technical developments in translational medicine, the project will drive drug discovery and improve direct disease management by combining clinical, genetic and epidemiological expertise with modern molecular analysis techniques and newly-developed tools in bioinformatics.



Duration
5 Years



Budget
20.8 Mio €



11 Countries
31 Partners

BIOMAP Vision

To better define the heterogeneity and homogeneous aspects of atopic dermatitis and psoriasis and to develop new concepts for taxonomy and patient stratification.

“By joining the expertise from academia and pharmaceutical industry, and by analysing a collection of harmonised clinical and molecular data from nearly a million sufferers, atopic dermatitis and psoriasis will be identified as a series of different diseases rather than just one disease, each with a characteristic molecular ‘signature’.”



Prof. Stephan Weidinger Coordinator
University of Kiel

“Our goal is to understand these diseases as comprehensively as possible. Any molecularly defined endotypes we will find, will help to drive the next generation of precision therapies that can improve the lives of patients.”

Dr Paul Bryce Project lead
Sanofi



Key Problems



High disease heterogeneity



Outdated disease classification



Limited understanding of underlying mechanisms



Lack of biomarkers for disease and therapy prediction



Insufficient infrastructure for global access to samples and data

Interdisciplinary Team

Within its multidimensional and impact-oriented approach, BIOMAP brings together key stakeholder groups from international research areas and industry partners.

External Advisory Groups such as patient organisations, representatives from clinical research and research ethics will complement the expertise of the consortium. They will provide guidance to obtain a clearer picture of similarities and differences in atopic dermatitis and psoriasis aiming at better drug development which will ultimately lead to improved treatment opportunities. Additionally, external advisors will provide support on scientific and ethical issues and ensure that BIOMAP operates with a patient-centric approach.